Anthem Biosciences Limited
Founded in 2006, Anthem Biosciences Ltd provides integrated CRDMO services and specializes in manufacturing specialty ingredients, focusing on both New Chemical Entities and New Biological Entities, with platforms like RNA interference and Antibody-Drug Conjugates.
What Anthem files
- Others29
- Investor Meet18
- Updates11
- Important6
- PPTs5
- Board Meeting4
Anthem Biosciences has successfully settled the upside sharing arrangement of approximately 127.68 Cr arising from the divestment by Viridity Tone LLP, fulfilling the terms approved by public shareholders and distributing the amount to the designated principal shareholders.
Anthem Biosciences reported Q1 FY27 revenues of Rs. 418 crores, EBITDA of Rs. 176 crores (40% margin), and PAT of Rs. 120 crores (27.1% margin), with a net cash position of Rs. 1,720 crores. Management acknowledged Q1 was soft due to delivery timing shifts but expressed confidence in full-year recovery...
Anthem Biosciences Limited has submitted the Exchange the voting results and a copy Srutinizers report of the 20th Annual General Meeting held on July 22, 2026.
Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Cr, down 22.6% YoY due to delivery timing shifts. EBITDA was ₹175.5 Cr (39.6% margin) and PAT ₹119.9 Cr (27.1% margin). Management expects strong H2FY27 deliveries and sustained industry-leading margins.